Nexalin Technology, Inc.

NXL

Healthcare Medical Devices

Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024.

Revenue
−82.7%
EPS
−10.0%
Free cash flow
−97.2%

Quarter to June 2026, against a year earlier

1.47 0.07 +5.00%
Market cap
$1.7M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
5/9
Net debt / EBITDA
0.4×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
103.92 30.30 25.03 32.09
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.12) (7.96) (4.03) (3.87)
P/B ratio
3.42 2.44 2.39 4.59
EV/Sales
76.22 17.97 15.22 27.49
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(1.00) (0.45) (0.76) (0.94)
Current Ratio
13.48 4.85 4.07 1.25
Net Debt/EBITDA
1.86 1.55 1.28 0.45
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(72.02%) (91.49%) (135.06%) (145.60%)
Free Cash Flow Yield
(73.25%) (131.04%) (80.07%) (90.92%)
Free Cash Flow per Share
(2.51) (2.16) (2.72) (2.63)
Book value per Share
8.05 6.87 4.37 2.16
Free Cash Flow
(1.49) (1.18) (1.79) (1.85)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026